{"id":633573,"date":"2025-09-16T16:56:16","date_gmt":"2025-09-16T20:56:16","guid":{"rendered":"https:\/\/www.singlecare.com\/blog\/?p=633573"},"modified":"2025-09-16T17:01:00","modified_gmt":"2025-09-16T21:01:00","slug":"bmi-for-mounjaro","status":"publish","type":"post","link":"https:\/\/www.singlecare.com\/blog\/bmi-for-mounjaro\/","title":{"rendered":"BMI for Mounjaro: Considerations for weight loss"},"content":{"rendered":"

Mounjaro<\/span><\/a> (tirzepatide) is a once-weekly injectable prescription drug that is approved by the Food and Drug Administration (FDA) for use in adults with <\/span>Type 2 diabetes<\/span><\/a>. Together with lifestyle changes like a reduced-calorie <\/span>diet<\/span><\/a> and increased physical activity, Mounjaro helps control blood sugar levels. And although Mounjaro is not FDA approved for weight loss, healthcare providers often prescribe this drug <\/span>off-label<\/span><\/a> for this use because it slows stomach emptying, making you feel fuller for longer and reducing cravings. Mounjaro, made by drug company Eli Lilly, is classified as a <\/span>glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, also called a dual GIP\/GLP-1 agonist. When considering whether you\u2019re a candidate for Mounjaro, healthcare providers will consider various factors, including your body mass index (BMI).\u00a0<\/span><\/p>\n

Why BMI matters for Mounjaro<\/span><\/h2>\n

According to the Centers for Disease Control and Prevention (CDC), body mass index (BMI) is a measure of a person\u2019s weight relative to their height. It is a free, quick, easy, and reliable type of measurement, but it should always be considered along with other individual factors, such as blood pressure, cholesterol levels, and labs.<\/span><\/p>\n

But because Mounjaro is FDA approved as a diabetes drug, its official prescribing information does not refer to BMI, <\/span>obesity<\/span><\/a>, or overweight as a qualification for use. Still, healthcare providers may consider BMI with other factors, such as a patient\u2019s <\/span>hemoglobin A1c<\/span><\/a> (a measure of blood sugar control over a three-month period), before prescribing Mounjaro for Type 2 diabetes. They may also ask about the patient\u2019s lifestyle habits, perform a physical exam, and assess their risk of other health problems. For example, even if you don\u2019t have Type 2 diabetes, they may decide you are an appropriate candidate for Mounjaro if you have obesity or if you\u2019re overweight with a weight-related medical condition, such as hypertension (<\/span>high blood pressure<\/span><\/a>) or <\/span>high cholesterol<\/span><\/a>.\u00a0<\/span><\/p>\n

For an FDA-approved weight loss medication, such as <\/span>Zepbound<\/span><\/a>\u2014which contains tirzepatide, the same active ingredient as Mounjaro\u2014the prescribing information <\/span>does<\/span><\/i> refer to weight. Specifically, the <\/span>Zepbound prescribing information<\/span><\/a> notes that the drug is FDA approved for weight loss and long-term weight management in adults with obesity\u2014or adults with overweight who have at least one weight-related medical condition. Zepbound is also <\/span>FDA approved<\/span><\/a> for adults with moderate to severe obstructive <\/span>sleep apnea<\/span><\/a> and obesity.\u00a0<\/span><\/p>\n

BMI requirements for Mounjaro<\/span><\/h2>\n

There are no specific guidelines that state BMI requirements for Mounjaro. The prescribing information does not list BMI, obesity, or overweight as criteria for use. Still, healthcare providers often consider BMI when prescribing Mounjaro off-label for weight loss, along with other individual factors. Standard <\/span>BMI categories<\/span><\/a> are:<\/span><\/p>\n